Drug intelligence / Profile preview

HL231

Development stage: Preclinical
Lead developer: Hanlim Pharm. Co., Ltd.
Modality: Small Molecules
Administration: Inhalation

Overview

HL231 is a small molecule new chemical entity (NCE) being developed by Hanlim Pharmaceuticals for the treatment of rheumatoid arthritis. Currently in the pre-clinical stage of development, it is part of Hanlim's discovery pipeline focused on inflammatory and autoimmune conditions. Specific molecular targets and mechanisms of action have not been publicly disclosed by the developer, but it is categorized as a novel therapeutic candidate within their NCE discovery program.

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on HL231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL231.

Explore the full profile